Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1055 Monotherapy and Combination Therapy in Malignant Solid Tumors
NCT06391775Phase 2Terminated
- Sponsor
- Genmab
- Start
- May 2024
- Primary completion
- Nov 2025
- Modality
- IgG Antibodies, Bispecific Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of GEN1055 in malignant solid tumor, sponsored by Genmab. Started May 2024; status: terminated.
02
Drugs
GEN1055
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT06391775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06391775.